Mersana Therapeutics, Inc. (MRSN)
NASDAQ: MRSN · Real-Time Price · USD
0.3189
-0.0161 (-4.81%)
At close: May 9, 2025, 4:00 PM
0.3340
+0.0151 (4.74%)
After-hours: May 9, 2025, 7:44 PM EDT
Mersana Therapeutics Stock Forecast
MRSN's stock price has decreased by -90.62% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
According to 2 professional analysts, the 12-month price target for Mersana Therapeutics stock ranges from a low of $3.00 to a high of $5.00. The average price target of $4.00 forecasts a 1,154.31% increase in the stock price over the next year.
Price Target: $4.00 (+1,154.31%)
Analyst Consensus: Buy
* Price targets were last updated on Aug 27, 2024.
Analyst Ratings
The average analyst rating for Mersana Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
Rating | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 |
---|---|---|---|---|---|---|
Strong Buy | 3 | 3 | 3 | 3 | 3 | 1 |
Buy | 1 | 1 | 2 | 2 | 2 | 1 |
Hold | 2 | 2 | 2 | 2 | 2 | 1 |
Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Total | 6 | 6 | 7 | 7 | 7 | 3 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
William Blair | William Blair | Buy Initiates n/a | Buy | Initiates | n/a | n/a | Feb 6, 2025 |
Citigroup | Citigroup | Strong Buy Maintains $6 → $5 | Strong Buy | Maintains | $6 → $5 | +1,467.89% | Aug 27, 2024 |
Baird | Baird | Hold Maintains $4 → $3 | Hold | Maintains | $4 → $3 | +840.73% | Aug 14, 2024 |
JP Morgan | JP Morgan | Sell → Hold Upgrades $5 | Sell → Hold | Upgrades | $5 | +1,467.89% | Mar 19, 2024 |
Wedbush | Wedbush | Hold → Buy Upgrades $2 → $7 | Hold → Buy | Upgrades | $2 → $7 | +2,095.05% | Feb 29, 2024 |
Financial Forecast
Revenue This Year
30.44M
from 40.50M
Decreased by -24.83%
Revenue Next Year
25.18M
from 30.44M
Decreased by -17.29%
EPS This Year
-0.73
from -0.56
EPS Next Year
-0.66
from -0.73
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | 55.7M | 44.9M | 43.6M | ||
Avg | 30.4M | 25.2M | 20.9M | ||
Low | n/a | n/a | n/a |
Revenue Growth
Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | 37.4% | 47.6% | 73.1% | ||
Avg | -24.8% | -17.3% | -16.9% | ||
Low | - | - | - |
EPS Forecast
EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | -0.34 | -0.19 | -0.56 | ||
Avg | -0.73 | -0.66 | -0.76 | ||
Low | -0.92 | -0.87 | -0.88 |
EPS Growth
EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | - | - | - | ||
Avg | - | - | - | ||
Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.